Recent advances in community-acquired pneumonia: Inpatient and outpatient

Chest

Volumn 131, Issue 4, 2007, Pages 1205-1215

  Niederman, Michael S ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Community acquired pneumonia; Drug resistance; Methicilllin resistant pneumonia; Severe pneumonia; Severity index; Staphylococcus aureus; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; DROTRECOGIN; ERYTHROMYCIN; FLUCLOXACILLIN; GATIFLOXACIN; GENTAMICIN; HYDROCORTISONE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TELITHROMYCIN; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTINUOUS INFUSION; DISEASE COURSE; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; ERYTHEMA; HEART ARRHYTHMIA; HOSPITAL CARE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIVER NECROSIS; OUTPATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; SCORING SYSTEM; SINGLE DRUG DOSE; STEROID THERAPY; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TACHYCARDIA; VACCINATION;

EID: 34247279363     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-1994     Document Type: Article

References (46)

1. Kaplan V, Clermont G, Griffin MF, et al. Pneumonia: still the old man's friend? Arch Intern Med 2003; 163:317-323
2. Koivula I, Sten M, Makela PH. Prognosis after community-acquired pneumonia in the elderly: a population-based 12 year follow-up study. Am J Med 1999; 159:1550-1555
3. Niederman MS, McCombs JI, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20:820-837
4. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005; 118:384-392
5. Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006; 27:9-11
6. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33:952-961
7. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006; 27:151-157
8. Goss CH, Rubenfeld GD, Park DR, et al. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted ot a public hospital. Chest 2003; 124:2148-2155
9. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174:84-93
10. Almirall J, Bolibar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125:1335-1342
11. Masia M, Gutierrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005; 128:2223-2229
12. Boussekey N, Leroy O, Georges H, et al. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005; 33:257-263
13. Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006; 32:469-472
14. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41:139-148
15. Lujan ML, Gallego M, Fontanals D, et al. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med 2004; 32:625-631
16. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230-237
17. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288-1297
18. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005; 41:118-121
19. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 100-107
20. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128:2732-2738
21. De Roux A, Marcos MA, Garcia E, et al. Viral community-acquired pneumonia in nonimmunocompromised adults. Chest 2004; 125:1343-1351
22. El Solh AA, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003; 167:1650-1654
23. Wang JL, Chen KY, Fang CT, et al. Changing bacteriology of adult community-acquired lung abscess in Taiwan: Klebsiella pneumoniae versus anaerobes. Clin Infect Dis 2005; 40:915-922
24. Menendez R, Torres A, Zalacain R, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005; 172:757-762
25. Van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60:672-678
26. Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42:73-81
27. Morganroth J, Dimarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005; 128:3398-3406
28. Loeb M, Carusone SC, Goeree R, et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. JAMA 2006; 295:2503-2510
29. Lonks JR, Goldmann DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 2005; 40:1657-1664
30. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352-1361
31. Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 4:415-420
32. Blasi F, Tarsia P. Value of short-course antimicrobial therapy in community-acquired pneumonia. Int J Antimicrob Agents 2005; 26: S148-S155
33. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-760
34. El Moussaui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 32:1355
35. Nathan RV, Rhew DC, Murray C, et al. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med 2006; 119:512:e1-e7
36. Leroy O, Saux P, Bedos JP, et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128:172-183
37. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171:242-248
38. Houck PM. Antibiotics and pneumonia: is timing everything or just a cause of more problems? Chest 2006; 130:1-3
39. Hiramatsu K, Niederman MS. Health-care-associated pneumonia: a new therapeutic paradigm. Chest 2005; 128:3784-3787
40. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture positive patients. Chest 2005; 128:3854-3862
41. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006; 130:11-15
42. Metersky ML, Sweeney TA, Getzow MB, et al. Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours? Chest 2006; 130:16-21
43. Metersky ML, Ma A, Bratzler DW, et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004; 169:342-347
44. Walker FJ, Singleton RJ, Bulkow LR, et al. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin Infect Dis 2005; 40:1730-1735
45. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-1764
46. Fisman DN, Abrutyn E, Spaude KA, et al. Prior pneumococcal vaccination is associated with reduced death, complications and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006; 42: 1093-1101